StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT - Free Report) in a report published on Wednesday. The firm issued a hold rating on the stock.
A number of other research analysts have also recently weighed in on the stock. HC Wainwright raised their price objective on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a "buy" rating in a research note on Thursday, October 24th. JMP Securities reaffirmed a "market outperform" rating and set a $10.00 price target on shares of DBV Technologies in a research report on Tuesday, December 10th.
Read Our Latest Analysis on DBV Technologies
DBV Technologies Stock Down 1.9 %
DBVT stock traded down $0.06 during trading on Wednesday, hitting $3.09. The company had a trading volume of 24,330 shares, compared to its average volume of 70,908. The firm has a market cap of $63.56 million, a PE ratio of -0.69 and a beta of 0.64. The firm has a 50-day moving average price of $3.36 and a 200-day moving average price of $3.87. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $9.90.
About DBV Technologies
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Articles
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
